

Different inhibition of $G\beta\gamma$ -stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a $G\beta\gamma$ -dependent regulator of PI3K γ enzymatic activity

Aliaksei Shymanets*, Prajwal*, Oscar Vadas†¹, Cornelia Czupalla*, Jaclyn LoPiccolo‡, Michael Brenowitz§, Alessandra Ghigo||, Emilio Hirsch||, Eberhard Krause¶, Reinhard Wetzker***, Roger L. Williams†, Christian Harteneck* and Bernd Nürnberg*²

*Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, and Interfaculty Centre of Pharmacogenomics and Pharmaceutical Research, University of Tübingen, 72074 Tübingen, Germany

†Medical Research Council, Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge CB2 0QH, U.K.

‡Department of Molecular Pharmacology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, U.S.A.

§Department of Biochemistry, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, U.S.A.

||Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, 10126 Turin, Italy

¶Mass Spectrometry Group, Leibniz Institute for Molecular Pharmacology, 13125 Berlin, Germany

***Department of Molecular Cell Biology, Centre for Molecular Biomedicine, Jena University Hospital, 07745 Jena, Germany

Class IB phosphoinositide 3-kinases γ (PI3K γ) are second-messenger-generating enzymes downstream of signalling cascades triggered by G-protein-coupled receptors (GPCRs). PI3K γ variants have one catalytic p110 γ subunit that can form two different heterodimers by binding to one of a pair of non-catalytic subunits, p87 or p101. Growing experimental data argue for a different regulation of p87–p110 γ and p101–p110 γ allowing integration into distinct signalling pathways. Pharmacological tools enabling distinct modulation of the two variants are missing. The ability of an anti-p110 γ monoclonal antibody [mAb(A)_{p110 γ}] to block PI3K γ enzymatic activity attracted us to characterize this tool in detail using purified proteins. In order to get insight into the antibody–p110 γ interface, hydrogen–deuterium exchange coupled to MS (HDX-MS) measurements were performed demonstrating binding of the monoclonal antibody to the C2 domain in p110 γ , which was accompanied by conformational changes in the helical

domain harbouring the $G\beta\gamma$ -binding site. We then studied the modulation of phospholipid vesicles association of PI3K γ by the antibody. p87–p110 γ showed a significantly reduced $G\beta\gamma$ -mediated phospholipid recruitment as compared with p101–p110 γ . Concomitantly, in the presence of mAb(A)_{p110 γ} , $G\beta\gamma$ did not bind to p87–p110 γ . These data correlated with the ability of the antibody to block $G\beta\gamma$ -stimulated lipid kinase activity of p87–p110 γ 30-fold more potently than p101–p110 γ . Our data argue for differential regulatory functions of the non-catalytic subunits and a specific $G\beta\gamma$ -dependent regulation of p101 in PI3K γ activation. In this scenario, we consider the antibody as a valuable tool to dissect the distinct roles of the two PI3K γ variants downstream of GPCRs.

Key words: $G\beta\gamma$, G-protein, p101, p87, phosphoinositide 3-kinase γ (PI3K γ), signal transduction.

INTRODUCTION

Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that transduce extracellular signals to trigger PtdIns(3,4,5) P_3 synthesis, an essential second messenger at the plasma membrane. PtdIns(3,4,5) P_3 , together with its metabolites, PtdIns(3,4) P_2 and PtdIns(3,5) P_2 , play fundamental roles in the regulation of basic cellular processes, such as proliferation, differentiation, growth and chemotaxis [1–8]. Class I PI3Ks are heterodimers composed of a catalytic (p110) and a non-catalytic subunit of the p85- or p101-type. Based on their interaction with non-catalytic subunits and their specific modes of regulation, class I PI3Ks can be further subdivided into class IA and class IB [2,3,9–12]. Class IA is characterized by heterodimers consisting of a catalytic p110 α , p110 β or p110 δ subunit associated with a p85-type non-catalytic subunit, which has dual roles acting as an adaptor and a regulator [11,13–16]. Although the p85-type subunit is indispensable for

class IA PI3K stability and regulation, the p110 catalytic subunit determines the signalling specificity [17–24].

The class IB PI3Ks are represented by two enzymes consisting of one catalytic p110 γ subunit associated with either a p101 or a p87 (also known as p87^{PIKAP} or p84) non-catalytic subunit [25–29]. Both PI3K γ variants, i.e. p87–p110 γ and p101–p110 γ , are stimulated by $G\beta\gamma$ heterodimers released upon G-protein-coupled receptor (GPCR) activation and by active Ras proteins [25–39]. The former view of p87 and p101 being redundant adaptors in $G\beta\gamma$ -mediated recruitment of PI3K γ variants to the membrane compartment [27–29] has been challenged by previous data showing a different contribution of $G\beta\gamma$ and Ras on the two PI3K γ variants [38]. In particular, distinct $G\beta\gamma$ -binding affinities of the non-catalytic subunits for p110 γ are intriguing [38,40,41]. These findings support data showing that PI3K γ variants integrate into different and independent signalling cascades [39,42–44]. We have previously reported

Abbreviations: GPCR, G-protein-coupled receptor; HDX-MS, hydrogen–deuterium exchange coupled to mass spectrometry; IB, immunoblotting; IP, immunoprecipitation; mAb, monoclonal antibody; PI3K, phosphoinositide 3-kinase.

¹ Present address: Department of Pharmaceutical Sciences, University of Geneva, CH-1211 Geneva 4, Switzerland.

² To whom correspondence should be addressed (email bernd.nuernberg@uni-tuebingen.de).

specific features for p87 and p101, such as diverse spatial and temporal distribution in human tissues and a different regulatory impact on p110 γ activity, which may contribute to the differential regulation of the PI3K γ variants [40,41]. These findings, in combination with the fact that only a single class IB catalytic subunit is present in cells, led us to postulate that p87 and p101 serve as signal-discriminating regulatory subunits defining specific functions for both p87–p110 γ and p101–p110 γ variants [41]. However, the exact molecular mechanisms that maintain the specificity and selectivity of the two PI3K γ variants are still unknown.

In the present study, we have identified and characterized a functional monoclonal anti-p110 γ antibody that specifically inhibits the G $\beta\gamma$ -induced p87–p110 γ enzymatic activity via contacting the C2 domain of p110 γ . Our results point to a differential impact of the non-catalytic subunits thereby revealing a specific G $\beta\gamma$ -dependent regulatory role of p101 in PI3K γ activation.

EXPERIMENTAL

Cell cultures and expression plasmids

Human embryonic kidney (HEK)-293 cells (German Resource Centre for Biological Materials) were cultured and transfected with expression plasmids encoding p101 and p110 γ as described previously [27,37,38]. For preparation of whole cell lysates, cells were directly lysed by adding 1 \times Laemmli sample buffer [45].

Expression and purification of recombinant proteins

Sf9 cells (fall armyworm ovary; Invitrogen) were cultured and infected as described previously [40]. Recombinant baculoviruses for expression of G $\beta_1\gamma_2$, PI3K γ and PI3K β subunits as well as their expression in Sf9 cells and purification of (His) $_6$ -tagged recombinant G β_1 (His) $_6\gamma_2$, (His) $_6$ p110 γ , p87–(His) $_6$ p110 γ , p101–(His) $_6$ p110 γ and p85–(His) $_6$ p110 β have been described elsewhere [38,40,41,46–48]. The pFastBacTM HTb baculovirus transfer vector (Invitrogen) was used to generate human full-length N-terminally (His) $_6$ -tagged H-Ras using BamHI/XhoI cloning site. H-Ras was produced in Sf9 insect cells and isolated using the Triton X-114 partition method as described previously [48,49]. The post-translational processing and lipidation of the protein was verified by MS analysis. Purified proteins were quantified by Coomassie Brilliant Blue staining after SDS/PAGE (10% acrylamide) with BSA as the standard. The proteins were stored at -80°C .

Hydrogen–deuterium exchange coupled to MS measurements

Hydrogen–deuterium exchange coupled to MS (HDX-MS) analyses of PI3K γ in the presence and absence of an anti-p110 γ monoclonal antibody [mAb(A) $_{p110\gamma}$] were performed following a similar protocol as described previously [21,48]. The rate of exchange of full-length p110 γ (His) $_6$ alone and in the presence of a 3-fold molar excess of mAb(A) $_{p110\gamma}$ were compared. Reactions were initiated by mixing 10 μl of protein solution with 40 μl of deuterated buffer containing 20 mM Hepes, pH 7.2, 50 mM NaCl and 0.5 mM EGTA. Deuteration reactions were run for 3, 30, 300 and 3000 s of on-exchange at 23°C , before being quenched by addition of 20 μl of a 2 M guanidinium chloride and 1.2% formic acid solution. The final deuterium concentration during the reaction was 78%. Every time point and state was a unique experiment and every HDX-MS experiment was repeated twice.

Samples were immediately frozen in liquid nitrogen and stored at -80°C for less than 1 week.

Analysis of the p110 γ deuteration level was done as described previously [48], by sequentially digesting the protein with pepsin, separating the fragments on a C $_{18}$ column and measuring the masses of peptides on a LTQ Orbitrap XL mass spectrometer. Manually selected peptides were then examined for deuterium incorporation by the HD-examiner software (Sierra Analytics). Results are presented as relative levels of deuteration with no correction for back exchange.

Gel electrophoresis, immunoblotting and antibodies

Generation and characterization of the anti-serum against the G β_1 subunit are detailed elsewhere [31,50]. Specific antibodies against p87 and p101 were gifts from Michael Schaefer (Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Leipzig, Germany) and Len Stephens (Babraham Institute, Cambridge, U.K.) respectively. mAb(A) $_{p110\gamma}$ and mAb(B) $_{p110\gamma}$ were raised against full-length human p110 γ using mouse hybridoma cells and were characterized earlier [37]. Large-scale preparations of mAb(A) $_{p110\gamma}$ were generated in co-operation with BioGenes. mAb(B) $_{p110\gamma}$ was as described earlier [31,40,41]. Generation and characterization of mAb(C) $_{p110\gamma}$, raised against the N-terminal 210 amino acids of catalytic p110 γ , was as detailed earlier [43]. Anti-Ras antibody was purchased from BD Biosciences. Anti-p110 β antibody was purchased from Cell Signaling Technology. Proteins were fractionated by SDS/PAGE (10% acrylamide) and transferred onto nitrocellulose membranes (HybondTM-C Extra, GE Healthcare). Visualization of specific antisera was performed using the ECL system (GE Healthcare) or the SuperSignal[®] West Pico Chemiluminescent Substrate (Pierce) according to the manufacturers' instructions. Chemiluminescence signals were estimated using the VersaDocTM 4000 MP imaging system (Bio-Rad Laboratories).

Immunoprecipitation of PI3K

Purified recombinant p110 γ , p87–p110 γ and p101–p110 γ and p85 α –p110 β variants were subjected to immunoprecipitation (IP) using mAb(A) $_{p110\gamma}$, mAb(B) $_{p110\gamma}$ or mAb(C) $_{p110\gamma}$. IP experiments were performed as detailed previously [41] with some modifications. In brief, Protein A–Sepharose CL-4B beads (GE Healthcare) were pre-incubated with or without antibody, washed, incubated overnight with cleared cell lysates or purified proteins and washed again. Proteins bound to beads were either tested for their lipid kinase activity or eluted by adding 1 \times Laemmli sample buffer [45] and subjected to SDS/PAGE.

Analysis of PI3K enzymatic activity

The lipid kinase activity of PI3K γ and analysis of G $\beta_1\gamma_2$, H-Ras and PI3K γ association with phospholipid vesicles were performed as described previously [32,34,40,41,46].

Analytical ultracentrifugation analyses

Molecular mass and complex stability of purified p87–p110 γ and p110–p110 γ heterodimers were analysed by sedimentation equilibrium analysis using a Beckman Optima XL-I centrifuge using the AN-60Ti rotor with the absorption optics set to 280 nm. Analyses were conducted in a buffer containing 20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 2 mM DTT and 0.033% deca(ethylene




Figure 1 mAb(A)_{p110γ} inhibits enzymatic activity of monomeric p110γ

(A) mAb(A)_{p110γ} does not interact with denatured catalytic p110γ subunit in immunoblots. Monomeric p110γ was expressed in and purified from Sf9 cells. Different amounts of the protein were subjected to SDS/PAGE (10% acrylamide) followed by IB using mAb(A)_{p110γ} or, mAb(B)_{p110γ}. (B) mAb(A)_{p110γ} binds intact p110γ. Purified recombinant p110γ was subjected to IP using mAb(A)_{p110γ} or p110γ-unspecific antibody as detailed in the Experimental section. Duplicates of immunoprecipitates were separated by SDS/PAGE (10% acrylamide) followed by IB with mAb(A)_{p110γ} or mAb(B)_{p110γ}. (C) mAb(A)_{p110γ} was tested for its ability to affect Gβ₁γ₂-induced lipid kinase activity of purified recombinant monomeric p110γ. The lipid kinase activity of enzyme (1.5 nM) was measured in the presence of 300 nM Gβ₁γ₂ (EC₅₀ value) and in the absence or presence of increased concentrations of mAb(A)_{p110γ}. The data shown here are mean values ± S.E.M. ($n=3$).

glycol) dodecyl ether (C₁₂E₁₀) at 10°C. Sample and buffer (120 μl each) were loaded into six-channel cell assemblies. Replicate scans were taken following a 24 h equilibration at 6000 rev/min and then following a second 24 h equilibration at 11 000 rev/min. Scans were also taken at 22 h at each speed so that equilibration could be confirmed. The equilibrium protein concentration distributions were globally analysed using the program HeteroAnalysis version 1.1.58 [51,52]. Sednterp version 20120828 Beta (<http://sednterp.unh.edu>) was used to calculate the partial specific volume of the proteins from their sequence and the density of the buffer from its composition neglecting the contribution of the detergent. The sedimentation parameters were corrected to standard conditions (20, w) using these values. The 280-nm molar absorption coefficients calculated from each protein's sequence were used to calculate the concentrations of the protein complexes (<http://web.expasy.org/protparam/>).

Statistical analysis

Results (means ± S.E.M.) were analysed using Student's *t* test (* $P \leq 0.05$; ** $P \leq 0.01$).

RESULTS

Inhibition of monomeric p110γ by mAb(A)_{p110γ}

A monoclonal anti-p110γ antibody [mAb(A)_{p110γ}] raised against full-length human catalytic p110γ subunit used in earlier IP experiments [37] displayed interesting features attracting our attention. mAb(A)_{p110γ} failed to visualize p110γ in immunoblots (Figure 1A); however, it was able to interact with the intact protein in solution enabling IP experiments (Figure 1B). The feature of recognizing native p110γ made it worthwhile to test whether mAb(A)_{p110γ} interferes with p110γ activity. As shown in Figure 1(C), incubation with mAb(A)_{p110γ} led to a drastic reduction in p110γ lipid kinase activity stimulated by Gβ₁γ₂, defining mAb(A)_{p110γ} as a putative PI3K γ inhibitor.

In order to test the selectivity of the mAb(A)_{p110γ} antibody, we measured its effect on the activity of the class IA PI3K β , another Gβγ-sensitive PI3K. Recombinant and functionally active Gβγ-sensitive p85α-p110β was purified following heterologous expression in Sf9 cells (Figures 2A and 2B). IP experiments (Figure 2C) as well as analysis of the immunoprecipitates in the lipid kinase assays (Figure 2D) showed complete lack of interaction between mAb(A)_{p110γ} and p85α-p110β. Correspondingly, mAb(A)_{p110γ} did not inhibit lipid kinase activity of purified p85α-p110β (Figure 2E).

Mapping of p110γ regions affected by interaction with mAb(A)_{p110γ}

Since mAb(A)_{p110γ} was generated by an immunization and selection protocol using full-length human catalytic p110γ subunit, the epitope of p110γ targeted by mAb(A)_{p110γ} was unknown. To determine the p110γ epitope recognized by mAb(A)_{p110γ}, we used HDX-MS. HDX-MS is a powerful technique that can map protein-protein and protein-lipid interactions, as well as provide useful information on the dynamics of proteins [53,54]. The technique is based on the differences in exchange rate of amide protons from a protein with solvent, a reaction that is influenced by secondary structure and solvent exposure.

To map the regions in p110γ that are affected by the interaction with mAb(A)_{p110γ}, we compared the HDX rates of p110γ in solution and when in a complex with mAb(A)_{p110γ}. A large proportion of the C2 domain shows a reduced HDX rate in the p110γ-mAb(A)_{p110γ} complex, suggesting that the antibody binds this region of p110γ (Figures 3A and 3B). More precisely, the most solvent-exposed part of the C2 domain, spanning residues 382–413, has a strongly reduced dynamics, probably stabilizing the β-strand underneath (residues 414–428). Interestingly, binding of mAb(A)_{p110γ} seems to induce allosteric changes in p110γ, as increased HDX rates are observed in two distinct domains of p110γ: the helical and kinase domains (Figure 3B). The increased dynamics in the p110γ helical domain (551–607, 622–630, 636–650) overlaps with the previously identified Gβγ-binding site (546–607) [48]. The two helices within the kinase domain that show increased dynamics (1035–1050) correspond to a region essential for inhibition of p110α activity by its regulatory subunit [55].

In summary, HDX-MS experiments revealed that mAb(A)_{p110γ} associates with the C2 domain of p110γ and induces conformational changes in the helical and kinase domains. Since both domains are important for PI3K γ regulation, binding of mAb(A)_{p110γ} to p110γ might affect kinase enzymatic activity.

Effect of mAb(A)_{p110γ} on p87–p110γ and p101–p110γ heterodimer activity

Class IB PI3K γ is present as two distinct functional p87–p110γ and p101–p110γ heterodimers *in vivo* [26,38,41,42]. We tested how mAb(A)_{p110γ} affects the enzymatic activities of these two PI3K γ variants stimulated by Gβ₁γ₂. Two additional monoclonal antibodies raised against full-length human catalytic p110γ subunit [mAb(B)_{p110γ}] and N-terminal amino acids 1–210 of p110γ [mAb(C)_{p110γ}] were also included in order to validate the specificity of interactions. As depicted in Figure 4(A), significant differences in the ability of the antibodies to affect lipid kinase activities of the two PI3K γ variants became apparent. Although incubation of p87–p110γ with mAb(A)_{p110γ} resulted in drastic reduction in Gβ₁γ₂-stimulated




Figure 2 mAb(A)_{p110γ} does not interact with Gβγ-sensitive PI3Kβ

(A) Stimulation of recombinant class IA PI3Kβ (p85α-p110β) lipid kinase activity in response to increasing concentrations of Gβ₁γ₂. The data shown here represent the average for three independent experiments. (B) Different amounts of purified recombinant p85α-p110β were subjected to SDS/PAGE (10% acrylamide) followed by IB using specific anti-p110β antibody. (C and D) Purified p85α-p110β was immunoprecipitated using mAb(A)_{p110γ} or p110β-unspecific antibody as described in the Experimental section. Obtained immunoprecipitates were analysed by IB using specific anti-p110β antibody (C) and tested in the lipid kinase assay in the absence or presence of 120 nM Gβ₁γ₂ (D). Shown here are one typical immunoblot and autoradiograph out of three independent experiments. (E) mAb(A)_{p110γ} was tested for its ability to affect Gβ₁γ₂-induced lipid kinase activity of purified recombinant p85α-p110β. The lipid kinase activity of enzyme (1.5 nM) was measured in the presence of 300 nM Gβ₁γ₂ (EC₅₀ value) and in the absence or presence of increased concentrations of mAb(A)_{p110γ}. The data shown here are mean values ± S.E.M. (n=3).

lipid kinase activity, inhibition of p101-p110γ activity by this antibody, at the concentrations tested, was weak. In contrast, mAb(B)_{p110γ} and mAb(C)_{p110γ} were ineffective in inhibiting enzymatic activity of either PI3Kγ variant under the identical experimental conditions (Figure 4A). The intriguing finding of the differential mAb(A)_{p110γ}-mediated effect on the two PI3Kγ variants showing only weak inhibition of p101-p110γ as compared with strong inhibition of p87-p110γ prompted us to check whether mAb(A)_{p110γ} was able to interact with p110γ when associated with p101. Comparable to monomeric p110γ (Figure 1A), immunoblotting (IB) analysis revealed that mAb(A)_{p110γ} does not recognize denatured p101-p110γ complex (Figure 4B). In contrast, mAb(B)_{p110γ} and mAb(C)_{p110γ} recognize p110γ in immunoblots (Figure 4B). Nonetheless, the capability of mAb(A)_{p110γ} to directly bind to p110γ when complexed with p101 could be verified by IP (Figure 4C).

Taken together, mAb(A)_{p110γ} inhibits Gβγ-stimulated lipid kinase activity of p87-p110γ more potently than of p101-p110γ.

Interaction of p87-p110γ or p101-p110γ heterodimers with phospholipid vesicles

The HDX-MS data demonstrate binding of mAb(A)_{p110γ} to the C2 domain of p110γ (Figure 3B). The C2 domain of p110γ, similarly to other C2 domains, is considered to mediate protein-lipid interactions [56–58]. This encouraged us

to check whether mAb(A)_{p110γ} interferes with Gβ₁γ₂-mediated association of p87-p110γ or p101-p110γ to phospholipid vesicles in the absence and presence of another known PI3Kγ regulator, i.e. H-Ras. Strikingly, mAb(A)_{p110γ} differently affected Gβ₁γ₂-mediated phospholipid vesicle association of PI3Kγ variants. Whereas mAb(A)_{p110γ} strongly reduced Gβ₁γ₂-mediated vesicle association of p87-p110γ in a concentration-dependent manner, association of p101-p110γ remained unchanged (Figure 5A). mAb(A)_{p110γ} did not change binding of p101-p110γ to phospholipid vesicles upon exposure to both regulators, Gβ₁γ₂ and H-Ras (Figure 5B). However, concomitant incubation with Gβ₁γ₂ and prenylated H-Ras partially rescued phospholipid vesicle association of p87-p110γ in the presence of mAb(A)_{p110γ}. Nonetheless, membrane association was impaired by high concentrations of mAb(A)_{p110γ} (Figure 5B). It should be pointed out that in these experiments p87, p101 and p110γ were found in ratios corresponding the starting condition suggesting that the stoichiometry of the PI3Kγ variants bound to phospholipid vesicles was not affected by mAb(A)_{p110γ} (Figure 5, grey or white bars compared with black bars). Control experiments excluded that the association of Gβγ or H-Ras to phospholipid vesicles was significantly affected by mAb(A)_{p110γ} (Table 1). High complex stability was supported by equilibrium analytical ultracentrifugation showing *K_d* values of ≤0.2 μM for p87-p110γ and ≤0.1 μM for p101-p110γ (Figure 6).

The interference of mAb(A)_{p110γ} with Gβγ-binding was tested by co-IP of p87-p110γ or p101-p110γ with Gβ₁γ₂ and H-Ras (Figure 7). In the case of p87-p110γ, a reduction in Gβ₁γ₂






Figure 4 Different impact of monoclonal anti-p110 γ antibodies on enzymatic activity of heterodimeric PI3K γ variants

(A) The monoclonal anti-p110 γ antibodies, mAb(A)_{p110 γ} , mAb(B)_{p110 γ} and mAb(C)_{p110 γ} , were tested for their ability to affect G $\beta_1\gamma_2$ -induced lipid kinase activity of purified recombinant p87–p110 γ and p101–p110 γ . PI3K γ variants (1.5 nM) were stimulated by G $\beta_1\gamma_2$ at EC₅₀ values, i.e. 300 nM for p87–p110 γ and 30 nM for p101–p110 γ . The data shown here are mean values \pm S.E.M. ($n=3$). (B) mAb(A)_{p110 γ} does not interact with the catalytic p110 γ subunit of denatured p101–p110 γ in immunoblots. Heterodimeric enzyme was expressed in and purified from Sf9 cells. Different amounts of the recombinant protein were subjected to SDS/PAGE (10% acrylamide) followed by IB using the monoclonal anti-p110 γ antibodies mAb(A)_{p110 γ} , mAb(B)_{p110 γ} or mAb(C)_{p110 γ} . (C) mAb(A)_{p110 γ} binds to the catalytic subunit of intact p101–p110 γ . Purified recombinant p101–p110 γ was subjected to IP using mAb(A)_{p110 γ} , mAb(B)_{p110 γ} , mAb(C)_{p110 γ} or p110 γ -unspecific antibody as described in the Experimental section. Duplicates of immunoprecipitates were separated by SDS/PAGE (10% acrylamide) followed by IB with mAb(A)_{p110 γ} or mAb(B)_{p110 γ} .

Table 1 mAb(A)_{p110 γ} does not change the association of G $\beta_1\gamma_2$ and H-Ras with phospholipid vesicles

Recombinant purified G $\beta_1\gamma_2$ dimers (600 nM) and H-Ras (1000 nM) were mixed with 28 nM p87–p110 γ or p101–p110 γ and incubated with phospholipid vesicles in the absence or presence of 25 nM or 120 nM mAb(A)_{p110 γ} . Aliquots of sedimented phospholipid vesicles and their supernatants were subjected to SDS/PAGE (10% acrylamide) followed by IB using antibodies specific for G β_{1-4} and H-Ras proteins. Chemiluminescence signals were estimated with a VersaDoc™ 4000 MP imaging system (Bio-Rad Laboratories). For calculation of phospholipid vesicle-associated proteins, signal intensities in the sedimented phospholipid vesicles and their supernatants were added and considered as 100%. Shown here are the mean values \pm S.E.M. for at least three separate experiments.

Incubation with PI3K γ variants	mAb(A) _{p110γ} (nM)	Association with lipid vesicles %	
		G $\beta_1\gamma_2$	H-Ras
p87–p110 γ	0	29.2 \pm 5.3	35.2 \pm 6.9
	25	24.7 \pm 5.2	34.1 \pm 7.3
	120	23.7 \pm 4.5	34.8 \pm 8.1
p101–p110 γ	0	31.4 \pm 4.8	32.2 \pm 7.2
	25	30.2 \pm 7.9	28.2 \pm 8.1
	120	32.1 \pm 7.9	29.3 \pm 5.9

monitored by G β_1 -immunoreactivity was evident, whereas H-Ras-levels remained unaffected (Figure 7). Taken together, the data show a mAb(A)_{p110 γ} -dependent inhibition of G $\beta_1\gamma_2$ -induced recruitment of p87–p110 γ to the lipid compartment. Next, we investigated the consequences for enzymatic activity.

Concentration-dependent inhibition of PI3K γ variants by mAb(A)_{p110 γ}

We studied concentration-dependent inhibition of variously stimulated lipid kinase activities of p87–p110 γ and p101–p110 γ in the presence of increasing concentrations either of the pan-PI3K inhibitor wortmannin (Figures 8A–8D) or mAb(A)_{p110 γ} (Figures 8E–8H). Wortmannin, which blocks all class I PI3Ks by covalent binding to a lysine residue in the ATP-binding pocket of p110 isoforms [59], inhibited both PI3K γ variants at similar IC₅₀ concentrations under all conditions tested and failed to differentiate between the two PI3K γ variants.

In the presence of mAb(A)_{p110 γ} , basal lipid kinase activities of the two PI3K γ variants were inhibited in a concentration-dependent manner with IC₅₀ values of 7.2 \pm 1.3 nM and 17.8 \pm 5.2 nM for p87–p110 γ and p101–p110 γ respectively (Figure 8E). Strikingly, the G $\beta_1\gamma_2$ -stimulated activity of p87–p110 γ was inhibited \sim 30-fold more potently as compared with the p101–p110 γ counterpart (IC₅₀ of 1.6 \pm 0.5 nM compared with 46.5 \pm 12.6 nM; Figure 8F). In contrast, mAb(A)_{p110 γ} inhibition of H-Ras-stimulated variants was indistinguishable (Figure 8G). When the enzymes were co-stimulated by G $\beta_1\gamma_2$ and H-Ras, p87–p110 γ was 10-fold more potently inhibited as compared with p101–p110 γ by mAb(A)_{p110 γ} (IC₅₀ of 4.3 \pm 0.4 nM compared with 49.5 \pm 4.9 nM; Figure 8H). Thus, mAb(A)_{p110 γ} not only represents a valuable experimental tool to understand the different regulation of PI3K γ variants but also serves to selectively intervene into G $\beta\gamma$ -induced p87–p110 γ lipid kinase activity.




Figure 5 Effect of mAb(A)_{p110γ} on the association of PI3K γ variants with phospholipid vesicles

mAb(A)_{p110γ} was tested for its ability to affect Gβ₁γ₂-mediated association (600 nM Gβ₁γ₂) of purified recombinant PI3K γ variants (28 nM) with phospholipid vesicles in the absence (A) or presence of 1000 nM H-Ras (B). Aliquots of supernatants and sedimented phospholipid vesicles were subjected to SDS/PAGE (10% acrylamide). Association of each PI3K γ subunits with phospholipid vesicles was analysed by IB using mAb(A)_{p110γ} and antibodies specific against p87 or p101. Chemiluminescence signals were estimated with a VersaDoc™ 4000 MP imaging system (Bio-Rad Laboratories). For calculation of phospholipid vesicle-associated subunits of PI3K γ variants, signal intensities in the sedimented phospholipid vesicles and their supernatants were added and considered as 100%. Shown here are the mean values \pm S.E.M. for at least three separate experiments.

DISCUSSION

We recently described p87–p110 γ as a constitutively and ubiquitously expressed class IB PI3K γ variant [41]. In contrast, p101–p110 γ appeared as an inducible counterpart which is up-regulated upon activation and expressed in various tissues side-by-side with p87–p110 γ . In line with this view, growing experimental evidence indicates a divergent function and regulation of the two class IB PI3K γ variants [38,39,42–44]. Unfortunately, pharmacological tools discriminating between the two variants are not available [60]. In the present study, we identified a monoclonal antibody mAb(A)_{p110γ} as a potent inhibitor of PI3K γ isoforms acting at low nanomolar concentrations. mAb(A)_{p110γ} blocked basal lipid kinase activities of either p87–p110 γ or p101–p110 γ with potencies comparable to that of wortmannin, an inhibitor acting at the ATP-binding site. Interestingly, enzymatic activities were differentially inhibited with a significant preference for p87–p110 γ following stimulation by Gβ γ . This preferential inhibition of p87–p110 γ activity by mAb(A)_{p110γ} persisted even in experiments stimulating the PI3K γ variants simultaneously with Ras and Gβ γ .

The mAb(A)_{p110γ} was generated using full-length human p110 γ protein for immunization and selection procedure and, therefore, the exact antibody–p110 γ interaction site was unknown [37,61]. HDX-MS, an approach that has provided insight into PI3K




Figure 6 Comparable complex stability of p87–p110 γ and p101–p110 γ measured by analytical sedimentation equilibrium

Three concentrations (0.5, 2.0 and 4.0 μ M) of p87–p110 γ (A) and p101–p110 γ (B) were centrifuged and analysed to yield the equilibrium concentration distributions of the protein complexes (measured by their absorption at 280 nm) as a function of the radial distance from the centre of the rotor at 6000 (\circ) and 11000 (\diamond) rev/min for each of the three sample channels. The unbroken lines depict the best non-linear least squares fit of the hetero-association model to each complex. The residuals of the fits are shown at the bottom of each channel along the dotted line at 0.0. Sedimentation equilibrium analysis yielded weight-average molecular masses (196.8 ± 7.8 kDa for p87–p110 γ and 206.6 ± 10.2 kDa for p101–p110 γ) which were slightly less than the values calculated from the sequences of the proteins (210.7 kDa for p87–p110 γ and 223.8 kDa for p101–p110 γ), assuming a 1:1 stoichiometry for the complexes. The K_d values determined from these data are presented in the Results section.

regulation at the membrane and by regulatory partners [21,48,62], identified dynamic changes within three domains of p110 γ upon association with mAb(A)_{p110γ}. Residues 382–428 in the C2 domain of p110 γ were protected from HDX, most probably due to binding of the antibody to this region. In addition, antibody–p110 γ interaction induced increased dynamics in both the helical and the kinase domain of p110 γ , probably as a result of allosteric modifications.

Generally, C2 domains have been associated with membrane interactions. The C2 domain of p110 γ was also proposed to be involved in the interaction of p110 γ with the plasma membrane [58]. However, recent data looking at lipid-binding sites of class I PI3Ks have identified the C-terminal helix of the kinase domain rather than the C2 domain to be involved in binding to lipids [21,48,63]. Our data obtained in phospholipid pull-down assays are in agreement with these recent data. The necessity of the C2 domain of p110 γ to act as the membrane




Figure 7 mAb(A)_{p110γ} affects binding of Gβ₁γ₂ to p87-p110γ

Purified recombinant p87-p110γ or p101-p110γ (0.375 μg of catalytic p110γ subunit) in the absence or presence of Gβ₁γ₂ (1.25 μg) and H-Ras (1.25 μg) were subjected to IP using mAb(A)_{p110γ} as described in the Experimental section. Duplicates of immunoprecipitates were separated by SDS/PAGE (10% acrylamide) followed by IB with mAb(B)_{p110γ}. Co-immunoprecipitated Gβ₁γ₂ and H-Ras were visualized using specific anti-Gβ₁γ₂ and anti-Ras antibodies. Weak unspecific chemiluminescence signals detected by anti-Ras antibody in PI3Kγ immunoprecipitates in the absence of Gβ₁γ₂ and H-Ras are caused by light chains of mAb(A)_{p110γ}.

interaction module in the regulation of PI3Kγ was not hitherto experimentally validated. Although Kirsch et al. [64] have shown that the phospholipid binding of a p110γ fragment comprising amino acids 740–1068 was significantly lower than the binding of full-length p110γ, this truncation construct lacked more than just the C2 domain (comprising residues 357–522). In addition to phospholipid binding, C2 domains have been reported to exhibit additional functions. In p110α, the C2 domain seems to be crucial for the inhibitory function of p85 on p110, whereas the C2 domain of p110β harbours a nuclear localization signal motif mediating translocation into the nucleus [11,15,65].

Our data argue for a different effect of mAb(A)_{p110γ} on Gβγ-mediated stimulation of p87-p110γ and p101-p110γ. HDX-MS analyses indicate that binding of mAb(A)_{p110γ} to the p110γ C2 domain induces allosteric changes in the helical domain. Since the helical domain is responsible for Gβγ binding [48], it is possible that the conformational changes directly affect the affinity of Gβγ for p110γ. Additionally, the different potencies by which mAb(A)_{p110γ} inhibits Gβγ stimulation of PI3Kγ variants may be a consequence of a distinct effect of the two non-catalytic subunits, i.e. p87 and p101, on PI3Kγ activity (Figure 9). Alternatively, since the p110γ helical domain is stabilized by the associated p87 or p101 regulatory subunits [48,66], one possibility of discriminative inhibition of PI3Kγ variants is that p101 protects




Figure 8 Discriminative inhibition of heterodimeric PI3Kγ variants by mAb(A)_{p110γ}

The activities of p87-p110γ or p101-p110γ either in the basal condition or in the presence of Gβ₁γ₂, H-Ras and Gβ₁γ₂ together with H-Ras were measured in the presence of increasing concentrations of pan-PI3K inhibitor wortmannin (A–D) or mAb(A)_{p110γ} (E–H). (A and E) The activities of PI3Kγ variants were measured under basal conditions with 7 nM (n=2) or 14 nM (n=1) kinase in the assay. (B and F) The activities of PI3Kγ variants (1.5 nM) were measured in the presence of EC₅₀ values of Gβ₁γ₂ (300 nM for p87-p110γ and 30 nM for p101-p110γ). (C and G) The activities of PI3Kγ enzymes (7 nM) were measured in the presence of EC₅₀ values of H-Ras (450 nM for p87-p110γ and 850 nM for p101-p110γ). (D and H) The activities of PI3Kγ variants (1.5 nM) were measured in the presence of EC₅₀ values of H-Ras (450 nM for p87-p110γ and 850 nM for p101-p110γ) and EC₅₀ values of Gβ₁γ₂ (300 nM for p87-p110γ and 30 nM for p101-p110γ). The data shown in graphs and in tables are the mean values ± S.E.M. for at least three separate experiments.




Figure 9 Schematic representation of putative molecular mechanisms induced by mAb(A)_{p110 γ} resulting in discriminative inhibition of the PI3K γ variants

(A) Effect of mAb(A)_{p110 γ} on the basal states of the PI3K γ variants. Binding of mAb(A)_{p110 γ} to the C2 domain mediates allosteric modulation of residues 551–650 in the helical domain and residues 1035–1050 located in helices $\kappa\alpha 9$ and $\kappa\alpha 10$ of the C-terminal lobe of the kinase domain. These helices play an important role in allosteric activation of p110 γ , as was shown in the case of Ras stimulation [35]. mAb(A)_{p110 γ} -induced structural change of the kinase domain may interfere and reduce the basal lipid kinase activities of p87–p110 γ and p101–p110 γ . Slight protection of p101–p110 γ basal lipid kinase activity from the inhibitory effect of mAb(A)_{p110 γ} is in line with the previous data showing stimulatory modulation of p110 γ by p101 independently of its G $\beta\gamma$ adaptor function [41]. (B) Effect of mAb(A)_{p110 γ} on the PI3K γ variants stimulated by G $\beta\gamma$. Binding of mAb(A)_{p110 γ} to the C2 domain of p110 γ causes allosteric exposure of a region (residues 551–650) in the helical domain which also includes crucial amino acids involved in interaction with G $\beta\gamma$, Arg⁵⁵² and Lys⁵⁵³ [48]. This results in allosteric interference of mAb(A)_{p110 γ} with G $\beta\gamma$ binding to p110 γ . p101 was shown to be also involved in interaction with G $\beta\gamma$ via putative G $\beta\gamma$ -binding domain (G $\beta\gamma$ BD) located in the C-terminal region of p101 [48]. In contrast with p101, p87 contributed much lesser (if at all) to G $\beta\gamma$ interaction [28,38,41,48]. In the scenario of discriminative inhibition, mAb(A)_{p110 γ} disrupts p110 γ –G $\beta\gamma$ interaction in a similar way for each PI3K γ variant, whereas unaltered G $\beta\gamma$ binding capacity of p101 still allows effective translocation of p101–p110 γ and regulatory activity. In contrast, p87–p110 γ showed a reduced capability to interact with G $\beta\gamma$ in the presence of mAb(A)_{p110 γ} , resulting in drastic reduction in enzymatic activity. Indicated are PtdIns(4,5)P₂, PtdIns(3,4,5)P₃, the Ras-binding domain (RBD, residues 220–311), the C2 domain (residues 357–522), the helical domain (residues 545–725), the kinase domain (residues 726–1092) of p110 γ [58] and putative G $\beta\gamma$ BD of p101 [48].

from allosteric changes induced by mAb(A)_{p110 γ} more than p87 does. This would explain the reduced inhibitory effect of the antibody for the p101–p110 γ heterodimer compared with p87–p110 γ and to p110 γ .

Ample evidence suggests that p101 acts as a G $\beta\gamma$ adaptor [26,32,37,38]. Since p101 is able to rescue the stimulatory effect of G β_1 mutants deficient in stimulating p110 γ [40] and enhance G $\beta\gamma$ -induced stimulation of lipid-associated p110 γ [41], we characterize p101 as a G $\beta\gamma$ -dependent regulator of PI3K γ enzymatic activity. HDX-MS analysis on the p101–p110 γ complex has identified two regions within the C-terminal part of p101 to mediate PI3K γ activation by G $\beta\gamma$ [48]. In contrast, whether p87 functionally interacts with G $\beta\gamma$ remains an open question. Although p87 exhibits a significant degree of homology with p101 at the C-terminal region [27–29], up to now we could not find any evidence that it displays a G $\beta\gamma$ -adaptor function or serves as a G $\beta\gamma$ -dependent regulator [38,40,41]. Therefore, we suppose that in the presence of G $\beta\gamma$, mAb(A)_{p110 γ} induces structural alterations in the helical domain that result in more drastic consequences for p87–p110 γ than for p101–p110 γ on phospholipid vesicle recruitment and enzymatic activation.

Taken together, we have characterized the inhibitory action of the monoclonal anti-p110 γ antibody mAb(A)_{p110 γ} , mapped the antibody–p110 γ interface and present new structure–function

insights into PI3K γ activity. Specific features of mAb(A)_{p110 γ} to differentially block G $\beta\gamma$ -mediated association of p87–p110 γ and p101–p110 γ , and hence their enzymatic activities, provide the basis for a selective inhibition of G $\beta\gamma$ -initiated hormonal pathways of PI3K γ variants and argues for a specific G $\beta\gamma$ -dependent regulatory role for p101 in PI3K γ activation. This supports the idea of a differential regulatory impact of p87 and p101 on PI3K γ activation.

ACKNOWLEDGEMENTS

The expert technical assistance of Renate Riehle and Rosi Maier is greatly appreciated. We thank all members of the Nürnberg laboratory previously located in Düsseldorf and in Tübingen. We thank John Burke, Olga Perisic, Mark Skehel, Sarah Maslen, Farida Begum and Sew-Yeu Peak-Chew for help with the HDX-MS setup.

AUTHOR CONTRIBUTION

Aliaksei Shymanets, Christian Harteneck and Bernd Nürnberg designed the study. Aliaksei Shymanets, Prajwal, Oscar Vadas, Cornelia Czupalla, Jaclyn LoPiccolo, Alessandra Ghigo and Eberhard Krause performed the experiments. Aliaksei Shymanets, Oscar Vadas, Michael Brenowitz, Eberhard Krause, Emilio Hirsch, Reinhard Wetzker, Roger Williams, Christian Harteneck and Bernd Nürnberg analysed and interpreted the data and wrote the paper.

FUNDING

This work was supported by the Deutsche Forschungsgemeinschaft [grant numbers IRTG 1302 (to B.N.) and RTG 1715 (to R.W.)]; Telethon [grant number GGP14106 (to E.H.)]; the Swiss National Science Foundation fellowship [grant number PA00P3_134202 (to O.V.)]; the European Commission fellowship [grant numbers FP7-PEOPLE-2010-IEF and N°275880 (to O.V.)]; and the Medical Research Council [grant number U10518430 (to R.W.)].

REFERENCES

- Bunney, T.D. and Katan, M. (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. *Nat. Rev. Cancer* **10**, 342–352 [CrossRef PubMed](#)
- Vanhaesebroeck, B., Guillemet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The emerging mechanisms of isoform-specific PI3K signalling. *Nat. Rev. Mol. Cell Biol.* **11**, 329–341 [CrossRef PubMed](#)
- Balla, T. (2013) Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol. Rev.* **93**, 1019–1137 [CrossRef PubMed](#)
- Klempner, S.J., Myers, A.P. and Cantley, L.C. (2013) What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. *Cancer Discov.* **3**, 1345–1354 [CrossRef PubMed](#)
- Megison, M.L., Gillory, L.A. and Beierle, E.A. (2013) Cell survival signaling in neuroblastoma. *Anticancer Agents Med. Chem.* **13**, 563–575 [CrossRef PubMed](#)
- Nagai, S., Kurebayashi, Y. and Koyasu, S. (2013) Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. *Ann. N.Y. Acad. Sci.* **1280**, 30–34 [CrossRef PubMed](#)
- Okkenhaug, K. (2013) Signaling by the phosphoinositide 3-kinase family in immune cells. *Annu. Rev. Immunol.* **31**, 675–704 [CrossRef PubMed](#)
- Fruman, D.A. and Rommel, C. (2014) PI3K and cancer: lessons, challenges and opportunities. *Nat. Rev. Drug Discov.* **13**, 140–156 [CrossRef PubMed](#)
- Balla, T. (2009) Finding partners for PI3K γ : when 84 is better than 101. *Sci. Signal.* **2**, pe35 [CrossRef PubMed](#)
- Fruman, D.A. (2010) Regulatory subunits of class I α PI3K. *Curr. Top. Microbiol. Immunol.* **346**, 225–244 [PubMed](#)
- Vadas, O., Burke, J.E., Zhang, X., Berndt, A. and Williams, R.L. (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. *Sci. Signal.* **4**, re2 [CrossRef PubMed](#)
- Jean, S. and Kiger, A.A. (2014) Classes of phosphoinositide 3-kinases at a glance. *J. Cell Sci.* **127**, 923–928 [CrossRef PubMed](#)
- Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G.A. and Backer, J.M. (1998) Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110 α catalytic subunit by the p85 regulatory subunit. *Mol. Cell Biol.* **18**, 1379–1387 [PubMed](#)
- Geering, B., Cutillas, P.R., Nock, G., Gharbi, S.I. and Vanhaesebroeck, B. (2007) Class I α phosphoinositide 3-kinases are obligate p85-p110 heterodimers. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 7809–7814 [CrossRef PubMed](#)
- Dbouk, H.A., Pang, H., Fiser, A. and Backer, J.M. (2010) A biochemical mechanism for the oncogenic potential of the p110 β catalytic subunit of phosphoinositide 3-kinase. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 19897–19902 [CrossRef PubMed](#)
- Zhang, X., Vadas, O., Perisic, O., Anderson, K.E., Clark, J., Hawkins, P.T., Stephens, L.R. and Williams, R.L. (2011) Structure of lipid kinase p110 β /p85 β elucidates an unusual SH2-domain-mediated inhibitory mechanism. *Mol. Cell* **41**, 567–578 [CrossRef PubMed](#)
- Gupta, S., Ramjaun, A.R., Haiko, P., Wang, Y., Warne, P.H., Nicke, B., Nye, E., Stamp, G., Alitalo, K. and Downward, J. (2007) Binding of Ras to phosphoinositide 3-kinase p110 α is required for Ras-driven tumorigenesis in mice. *Cell* **129**, 957–968 [CrossRef PubMed](#)
- Okkenhaug, K., Ali, K. and Vanhaesebroeck, B. (2007) Antigen receptor signalling: a distinctive role for the p110 δ isoform of PI3K. *Trends Immunol.* **28**, 80–87 [CrossRef PubMed](#)
- Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H. et al. (2008) Phosphoinositide 3-kinase p110 β activity: key role in metabolism and mammary gland cancer but not development. *Sci. Signal.* **1**, ra3 [CrossRef PubMed](#)
- Beer-Hammer, S., Zebadin, E., von Holleben, M., Alferink, J., Reis, B., Dresing, P., Grandi, D., Scheu, S., Hirsch, E., Sexl, V. et al. (2010) The catalytic PI3K isoforms p110 γ and p110 δ contribute to B cell development and maintenance, transformation, and proliferation. *J. Leukoc. Biol.* **87**, 1083–1095 [CrossRef PubMed](#)
- Dbouk, H.A., Vadas, O., Shymanets, A., Burke, J.E., Salamon, R.S., Khalil, B.D., Barrett, M.O., Waldo, G.L., Surve, C., Hsueh, C. et al. (2012) G protein-coupled receptor-mediated activation of p110 β by G $\beta\gamma$ is required for cellular transformation and invasiveness. *Sci. Signal.* **5**, ra89 [CrossRef PubMed](#)
- Luk, S.K., Piekorz, R.P., Nürnberg, B. and Tony To, S.S. (2012) The catalytic phosphoinositide 3-kinase isoform p110 δ is required for glioma cell migration and invasion. *Eur. J. Cancer* **48**, 149–157 [CrossRef PubMed](#)
- Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M.S., Diefenbacher, M., Stamp, G. and Downward, J. (2013) RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. *Cell* **153**, 1050–1063 [CrossRef PubMed](#)
- Burke, J.E. and Williams, R.L. (2015) Synergy in activating class I PI3Ks. *Trends Biochem. Sci.* **40**, 88–100 [PubMed](#)
- Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nürnberg, B. et al. (1995) Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. *Science* **269**, 690–693 [CrossRef PubMed](#)
- Stephens, L.R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., Smrcka, A.S., Thelen, M., Cadwallader, K., Tempst, P. and Hawkins, P.T. (1997) The G $\beta\gamma$ sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. *Cell* **89**, 105–114 [CrossRef PubMed](#)
- Voigt, P., Brock, C., Nürnberg, B. and Schaefer, M. (2005) Assigning functional domains within the p101 regulatory subunit of phosphoinositide 3-kinase γ . *J. Biol. Chem.* **280**, 5121–5127 [CrossRef PubMed](#)
- Suire, S., Coadwell, J., Ferguson, G.J., Davidson, K., Hawkins, P. and Stephens, L. (2005) p84, a new G $\beta\gamma$ -activated regulatory subunit of the type I β phosphoinositide 3-kinase p110 γ . *Curr. Biol.* **15**, 566–570 [CrossRef PubMed](#)
- Voigt, P., Dorner, M.B. and Schaefer, M. (2006) Characterization of p87^{PIKAP}, a novel regulatory subunit of phosphoinositide 3-kinase γ that is highly expressed in heart and interacts with PDE3B. *J. Biol. Chem.* **281**, 9977–9986 [CrossRef PubMed](#)
- Rubio, I., Rodriguez-Viciana, P., Downward, J. and Wetzker, R. (1997) Interaction of Ras with phosphoinositide 3-kinase γ . *Biochem. J.* **326**, 891–895 [PubMed](#)
- Leopoldt, D., Hanck, T., Exner, T., Maier, U., Wetzker, R. and Nürnberg, B. (1998) G $\beta\gamma$ stimulates phosphoinositide 3-kinase γ by direct interaction with two domains of the catalytic p110 subunit. *J. Biol. Chem.* **273**, 7024–7029 [CrossRef PubMed](#)
- Maier, U., Babich, A. and Nürnberg, B. (1999) Roles of non-catalytic subunits in G $\beta\gamma$ -induced activation of class I phosphoinositide 3-kinase isoforms β and γ . *J. Biol. Chem.* **274**, 29311–29317 [CrossRef PubMed](#)
- Rubio, I., Wittig, U., Meyer, C., Heinze, R., Kadereit, D., Waldmann, H., Downward, J. and Wetzker, R. (1999) Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase γ . *Eur. J. Biochem.* **266**, 70–82 [CrossRef PubMed](#)
- Maier, U., Babich, A., Macrez, N., Leopoldt, D., Gierschik, P., Illenberger, D. and Nürnberg, B. (2000) G $\beta_5\gamma_2$ is a highly selective activator of phospholipid-dependent enzymes. *J. Biol. Chem.* **275**, 13746–13754 [CrossRef PubMed](#)
- Pacold, M.E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C.T., Walker, E.H., Hawkins, P.T., Stephens, L., Eccleston, J.F. and Williams, R.L. (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ . *Cell* **103**, 931–943 [CrossRef PubMed](#)
- Suire, S., Hawkins, P. and Stephens, L. (2002) Activation of phosphoinositide 3-kinase γ by Ras. *Curr. Biol.* **12**, 1068–1075 [CrossRef PubMed](#)
- Brock, C., Schaefer, M., Reusch, H.P., Czupalla, C., Michalke, M., Spicher, K., Schultz, G. and Nürnberg, B. (2003) Roles of G $\beta\gamma$ in membrane recruitment and activation of p110 γ /p101 phosphoinositide 3-kinase γ . *J. Cell Biol.* **160**, 89–99 [CrossRef PubMed](#)
- Kurig, B., Shymanets, A., Bohnacker, T., Prajwal, Brock, C., Ahmadian, M.R., Schaefer, M., Gohla, A., Harteneck, C., Wymann, M.P. et al. (2009) Ras is an indispensable coregulator of the class I β phosphoinositide 3-kinase p87/p110 γ . *Proc. Natl. Acad. Sci. U.S.A.* **106**, 20312–20317 [CrossRef PubMed](#)
- Schmid, M.C., Avraamides, C.J., Dippold, H.C., Franco, I., Foubert, P., Ellies, L.G., Acevedo, L.M., Manglicmot, J.R., Song, X., Wrasidlo, W. et al. (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K γ , a single convergent point promoting tumor inflammation and progression. *Cancer Cell* **19**, 715–727 [CrossRef PubMed](#)
- Shymanets, A., Ahmadian, M.R., Kössmeier, K.T., Wetzker, R., Harteneck, C. and Nürnberg, B. (2012) The p101 subunit of PI3K γ restores activation by G β mutants deficient in stimulating p110 γ . *Biochem. J.* **441**, 851–858 [CrossRef PubMed](#)
- Shymanets, A., Prajwal, Bucher, K., Beer-Hammer, S., Harteneck, C. and Nürnberg, B. (2013) p87 and p101 subunits are distinct regulators determining class I β phosphoinositide 3-kinase (PI3K) specificity. *J. Biol. Chem.* **288**, 31059–31068 [CrossRef PubMed](#)
- Bohnacker, T., Marone, R., Collmann, E., Calvez, R., Hirsch, E. and Wymann, M.P. (2009) PI3K γ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P $_3$ pools in mast cells. *Sci. Signal.* **2**, ra27 [CrossRef PubMed](#)
- Perino, A., Ghigo, A., Ferrero, E., Morello, F., Santulli, G., Baillie, G.S., Damilano, F., Dunlop, A.J., Pawson, C., Walser, R. et al. (2011) Integrating cardiac PIP $_3$ and cAMP signaling through a PKA anchoring function of p110 γ . *Mol. Cell* **42**, 84–95 [CrossRef PubMed](#)

- 44 Brazzatti, J.A., Klingler-Hoffmann, M., Haylock-Jacobs, S., Harata-Lee, Y., Niu, M., Higgins, M.D., Kochetkova, M., Hoffmann, P. and McColl, S.R. (2012) Differential roles for the p101 and p84 regulatory subunits of PI3K γ in tumor growth and metastasis. *Oncogene* **31**, 2350–2361 [CrossRef PubMed](#)
- 45 Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680–685 [CrossRef PubMed](#)
- 46 Czapalla, C., Culo, M., Müller, E.C., Brock, C., Reusch, H.P., Spicher, K., Krause, E. and Nürnberg, B. (2003) Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms β and γ . *J. Biol. Chem.* **278**, 11536–11545 [CrossRef PubMed](#)
- 47 Shymanets, A., Ahmadian, M.R. and Nürnberg, B. (2009) G $\beta\gamma$ -copurified lipid kinase impurity from Sf9 cells. *Protein Pept. Lett.* **16**, 1053–1056 [CrossRef PubMed](#)
- 48 Vadas, O., Dbouk, H.A., Shymanets, A., Perisic, O., Burke, J.E., Abi Saab, W.F., Khalil, B.D., Harteneck, C., Bresnick, A.R., Nürnberg, B. et al. (2013) Molecular determinants of PI3K γ -mediated activation downstream of G-protein-coupled receptors (GPCRs). *Proc. Natl. Acad. Sci. U.S.A.* **110**, 18862–18867 [CrossRef PubMed](#)
- 49 Porfiri, E., Evans, T., Bollag, G., Clark, R. and Hancock, J.F. (1995) Purification of baculovirus-expressed recombinant Ras and Rap proteins. *Methods Enzymol.* **255**, 13–21 [CrossRef PubMed](#)
- 50 Leopoldt, D., Harteneck, C. and Nürnberg, B. (1997) G proteins endogenously expressed in Sf 9 cells: interactions with mammalian histamine receptors. *Naunyn Schmiedeberg's Arch. Pharmacol.* **356**, 216–224 [CrossRef PubMed](#)
- 51 Cole, J.L. (2004) Analysis of heterogeneous interactions. *Methods Enzymol.* **384**, 212–232 [CrossRef PubMed](#)
- 52 Cole, J.L., Lary, J.W., Moody, T.P. and Laue, T.M. (2008) Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. *Methods Cell Biol.* **84**, 143–179 [CrossRef PubMed](#)
- 53 Cao, J., Burke, J.E. and Dennis, E.A. (2013) Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A₂ superfamily with lipid substrates, inhibitors, and membranes. *J. Biol. Chem.* **288**, 1806–1813 [CrossRef PubMed](#)
- 54 Pirrone, G.F., Jacob, R.E. and Engen, J.R. (2015) Applications of hydrogen/deuterium exchange MS from 2012 to 2014. *Anal. Chem.* **87**, 99–118 [CrossRef PubMed](#)
- 55 Miller, M.S., Schmidt-Kittler, O., Bolduc, D.M., Brower, E.T., Chaves-Moreira, D., Allaire, M., Kinzler, K.W., Jennings, I.G., Thompson, P.E., Cole, P.A. et al. (2014) Structural basis of nSH2 regulation and lipid binding in PI3K α . *Oncotarget* **5**, 5198–5208 [PubMed](#)
- 56 Bittova, L., Sumandea, M. and Cho, W. (1999) A structure-function study of the C₂ domain of cytosolic phospholipase A₂. Identification of essential calcium ligands and hydrophobic membrane binding residues. *J. Biol. Chem.* **274**, 9665–9672 [CrossRef PubMed](#)
- 57 Verdaguer, N., Corbalan-Garcia, S., Ochoa, W.F., Fita, I. and Gomez-Fernandez, J.C. (1999) Ca²⁺ bridges the C₂ membrane-binding domain of protein kinase C α directly to phosphatidylserine. *EMBO J.* **18**, 6329–6338 [CrossRef PubMed](#)
- 58 Walker, E.H., Perisic, O., Ried, C., Stephens, L. and Williams, R.L. (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. *Nature* **402**, 313–320 [CrossRef PubMed](#)
- 59 Wymann, M.P., Bulgarelli-Leva, G., Zvelebil, M.J., Pirola, L., Vanhaesebroeck, B., Waterfield, M.D. and Panayotou, G. (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. *Mol. Cell. Biol.* **16**, 1722–1733 [PubMed](#)
- 60 Freitag, A., Prajwal, P., Shymanets, A., Harteneck, C., Nürnberg, B., Schächtele, C., Kubbutat, M., Totzke, F. and Laufer, S.A. (2015) Development of first lead structures for phosphoinositide 3-kinase-c2 γ inhibitors. *J. Med. Chem.* **58**, 212–221 [CrossRef PubMed](#)
- 61 Bondev, A., Bondeva, T. and Wetzker, R. (2001) Regulation of phosphoinositide 3-kinase γ protein kinase activity *in vitro* and in COS-7 cells. *Signal Transduction* **1**, 79–85 [CrossRef](#)
- 62 Wales, T.E. and Engen, J.R. (2006) Hydrogen exchange mass spectrometry for the analysis of protein dynamics. *Mass Spectrom. Rev.* **25**, 158–170 [CrossRef PubMed](#)
- 63 Burke, J.E., Perisic, O., Masson, G.R., Vadas, O. and Williams, R.L. (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 α (PIK3CA). *Proc. Natl. Acad. Sci. U.S.A.* **109**, 15259–15264 [CrossRef PubMed](#)
- 64 Kirsch, C., Wetzker, R. and Klinger, R. (2001) Anionic phospholipids are involved in membrane targeting of PI 3-kinase γ . *Biochem. Biophys. Res. Commun.* **282**, 691–696 [CrossRef PubMed](#)
- 65 Kumar, A., Redondo-Munoz, J., Perez-Garcia, V., Cortes, I., Chagoyen, M. and Carrera, A.C. (2011) Nuclear but not cytosolic phosphoinositide 3-kinase β has an essential function in cell survival. *Mol. Cell. Biol.* **31**, 2122–2133 [CrossRef PubMed](#)
- 66 Walser, R., Burke, J.E., Gogvadze, E., Bohnacker, T., Zhang, X., Hess, D., Kuenzi, P., Leitges, M., Hirsch, E., Williams, R.L. et al. (2013) PKC β phosphorylates PI3K γ to activate it and release it from GPCR control. *PLoS Biol.* **11**, e1001587 [PubMed](#)

Received 23 January 2015/13 April 2015; accepted 23 April 2015
Published on the Internet 19 June 2015, doi:10.1042/BJ20150099